Other · developed by REGENERON PHARMACEUTICALS
REGN20423 is an investigational agent studied in healthy volunteers and in atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07527923 | Phase 1 | Healthy Volunteer | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atopic DermatitisHealthy Volunteer
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →